ClinicalTrials.gg
RecruitingNCT07441382CLEAR-AFUpdated Jun 8, 2026

Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation

An interventional study of catheter ablation combined with LAAO (Left Atrial Appendage Occlusion) and Atrial Fibrillation Radiofrequency Ablation Only in Atrial Fibrillation (AF), Stroke and Hemorrhage, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
139th of 256
200 · median 235
Started
2026
with 47 others
No phase
200 of 377
100 open now
Primary completion
2027-05
later than 107 of 182 live
Registered
321st of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 139th largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 107 of the 182 other live ones, and was the 321st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common arrhythmia, significantly increasing the risk of stroke, heart failure, hospitalization and death in patients. Studies have shown that standardized anticoagulation can effectively reduce the risk of stroke by 64% and the risk of death by 26% in AF patients. Therefore, both European and American guidelines recommend standardized oral anticoagulation (OAC) as an important treatment strategy for stroke prevention in AF patients. However, the use of OAC may also increase the risk of bleeding in patients. Results from large AF anticoagulation randomized trials show that the annual risk of anticoagulation-related bleeding mortality is 2% to 3%. Therefore, according to the guidelines recommendations, assessing the bleeding risk is necessary in patients with anticoagulant indications.

Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischemic stroke in patients with AF. For patients with contraindications to long-term anticoagulation therapy, LAAO can be considered as an alternative strategy to oral anticoagulation (Class II B recommendation) to prevent ischemic stroke and thromboembolism. Multiple studies have shown that LAAO is non-inferior to warfarin and novel oral anticoagulants in stroke prevention for non-valvular AF patients. Age is not only a risk factor for stroke but also an important risk factor for bleeding. In the elderly population, especially those with frailty, the risk factors for both stroke and bleeding are often increased. Currently, there is insufficient evidence to support the use of OAC in frail elderly patients with relative anticoagulant contraindications. Therefore, elderly AF patients may be one of the potential beneficiary groups for LAAO. However, most previous clinical studies on LAAO were based on small sample sizes to analyze their safety and efficacy, and clinical data on the safety and efficacy of LAAO in this high-risk population of elderly AF patients are still limited. To address this, the study aims to conduct a multicenter randomized controlled trial to compare the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients with high bleeding risk, filling the gap in this research area.

To address these limitations, this multicenter randomized controlled trial is designed to evaluate the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients at high risk for bleeding. The primary objective of the study is to compare the 12-month incidence and time-to-occurrence of the composite clinical endpoint. This endpoint includes stroke/TIA, systemic embolism, ISTH-defined major bleeding. By establishing these metrics within the first year, the study aims to fill the current void in clinical evidence and provide a standardized treatment strategy for high-risk elderly patients. In addition to the primary endpoints, the study will conduct a comprehensive long-term evaluation extending to 24 months post-procedure to assess the durability of both treatment strategies. Secondary objectives include the assessment of perioperative safety, specifically focusing on serious intraoperative complications and major adverse events occurring within the first seven days after the LAAO procedure. The trial will also measure long-term rhythm control by tracking the rate of freedom from AF recurrence at the one-year and two-year marks. Furthermore, the study seeks to verify the hypothesized superiority of the ablation-plus-LAAO strategy in reducing the specific burden of anticoagulation-related major bleeding and stroke.

Beyond clinical safety and efficacy, the trial will analyze the practical aspects of the two interventions, including procedural success rates, operation duration, fluoroscopy time, and the total duration of hospitalization. A critical component of the research involves identifying specific risk factors associated with complications, with a specialized focus on how frailty scores influence procedural tolerance and long-term prognosis. The study will further explore how different types of AF respond to the LAAO strategy and assess the impact of each treatment on non-major bleeding events. Ultimately, the trial aims to determine which strategy offers a superior improvement in the overall quality of life for elderly patients, thereby optimizing future clinical guidelines.

Read the detailed description
  1. Study Framework and Design Rationale:

    This multicenter randomized controlled trial investigates the efficacy and safety of combining catheter ablation with Left Atrial Appendage Occlusion (LAAO) compared to catheter ablation plus long-term oral anticoagulation (OAC) in a frail elderly population. Given the technical and ethical complexities of blinding invasive surgical procedures and subsequent anticoagulation adjustments, an open-label design is utilized to facilitate individualized post-operative management that reflects real-world clinical practice.

  2. Randomization, Enrollment, and Implementation:

    Following the signing of the written Informed Consent Form (ICF), potential participants enter a rigorous screening phase to ensure compliance with predefined inclusion and exclusion criteria. Eligible subjects (Target N=200) are randomly assigned in a 1:1 ratio to either the Research Group (Ablation + LAAC) or the Control Group (Ablation + OAC) via a centralized Interactive Web Response System (IWRS). The randomization sequence is generated using SPSS 26.0 with stratified block randomization, using the clinical trial institution as the stratification factor. To minimize bias, the interval between randomization and treatment initiation is strictly targeted to be less than 24 hours. The procedures are performed by operators with over 3 years of experience and a minimum of 100 successful AF ablation and LAAC cases to minimize operator-dependent bias.

  3. Comprehensive Baseline and Clinical Assessments:

    A multidimensional baseline assessment is conducted, encompassing demographic data (BMI, lifestyle habits), clinical risk scores (CHA₂DS₂-VASc, HAS-BLED), and comprehensive geriatric assessments, including the Clinical Frailty Scale (CFS), cognitive function (MoCA/MMSE), and Activities of Daily Living (ADL). Detailed medical histories are recorded, including specific definitions for stroke types (TIA, RIND, CS), congestive heart failure (regardless of LVEF), peripheral vascular disease, and chronic kidney disease (eGFR \<60 mL/min/1.73m² per KDIGO guidelines). Laboratory evaluations at baseline include complete blood counts (WBC, Hb, PLT), coagulation markers (INR, PT, APTT), liver/renal functions, thyroid panels (FT3, FT4, TSH), and cardiac biomarkers (NT-ProBNP/BNP).

  4. Surgical Procedures and Follow-up Regimen:

    Surgical parameters for catheter ablation (ablation site, power, temperature, and acute pulmonary vein isolation) and LAAC (device brand/size, stability, and residual shunt) are documented in detail. The structured follow-up schedule occurs at 1, 3, 6, 12, and 24 months post-operation. Efficacy and safety monitoring involve 12/15-lead ECGs at every visit and 24-hour Holter monitoring at months 3, 6, 12, and 24 to quantify AF burden and recurrences (duration ≥30s). Imaging studies including Transthoracic Echocardiography (TTE) are performed at 6, 12, and 24 months, while the Research Group undergoes Transesophageal Echocardiography (TEE) or Cardiac CT (CCT) at 3 and 12 months to assess device stability, residual shunts, and Device-Related Thrombus (DRT), which directly informs antithrombotic therapy adjustments.

  5. Statistical Analysis Plan and Sample Size Rationale:

    As a pilot study, the sample size of 200 subjects (100 per group, including a 10%-15% anticipated dropout rate) is designed to estimate the parameters necessary for a future confirmatory trial rather than to provide definitive statistical power for the composite endpoint (stroke, systemic embolism, and ISTH-defined major bleeding). Statistical analysis will be performed using SPSS 26.0 based on the Intent-to-Treat (ITT) principle, utilizing the Full Analysis Set (FAS), Per-Protocol Set (PPS), and Safety Set (SS). Continuous variables will be compared using independent t-tests or non-parametric tests (Kruskal-Wallis), while categorical data will be analyzed via Chi-square or Fisher's Exact tests. Survival outcomes will be depicted using Kaplan-Meier curves and analyzed through Cox proportional hazard models or Fine-Gray competing risk models to account for non-cardiovascular mortality in the elderly population. Missing data for the primary endpoint will be handled using the Worst Case Carry Forward (WCCF) strategy and Tipping Point sensitivity analysis.

  6. Safety Monitoring, Quality Control, and Ethical Oversight:

    The study adheres to the Declaration of Helsinki and GCP guidelines. An independent Blinded Clinical Endpoint Committee (CEC), composed of cardiologists and neurologists not involved in the study, will perform centralized adjudications of all suspected endpoint events (stroke, systemic embolism, major bleeding, and death) to ensure objectivity. Adverse events (AEs) are classified by severity (Mild, Moderate, Severe) and reported within 24 hours if categorized as Serious Adverse Events (SAEs). Strict quality control measures include Standard Operating Procedures (SOPs), regular site monitoring (CRA) with Source Data Verification (SDV), and independent audits to ensure data traceability and integrity. Protocol Deviations (e.g., visit window violations) and Protocol Violations (e.g., enrollment errors) are systematically recorded and reported to the Ethics Committee.

  7. Data Management and Confidentiality:

Data are captured via Electronic Case Report Forms (eCRFs) with double-entry verification. A detailed Data Management Plan (DMP) governs external data, query resolution, and database locking procedures. All subject information is treated as strictly confidential, identifiable only by subject codes, and accessible only to authorized researchers, ethics committees, and regulatory authorities. Data backups are performed weekly on secure cloud servers, and records will be preserved for at least 5 years following the conclusion of the study.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Stroke
  • Hemorrhage
  • Frailty
  • Atrial Appendage
  • Catheter Ablation
  • Anticoagulants

Keywords

  • Atrial Fibrillation
  • Left Atrial Appendage Closure
  • Stroke
  • Hemorrhage
  • Anticoagulants
  • Frailty
  • Aged
  • Randomized Controlled Trial
  • Catheter Ablation
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (1) Age ≥ 75 years. (2) Confirmed diagnosis of non-valvular atrial fibrillation (paroxysmal or persistent). (3) CHA2DS2-VASc score ≥ 3 (high risk of stroke) . (4) Procedure-related criteria: Sequential Group: Participants who have received catheter ablation for non-valvular AF within 90 to 180 days prior to randomization. One-stop Group: Participants who are scheduled to undergo clinically indicated catheter ablation within 10 days after randomization. (5) Judged by the investigator to be able to tolerate the defined antithrombotic drug regimen. (6) Suitable to undergo Transesophageal Echocardiography (TEE) or Pulmonary Vein Computed Tomography (CT). (7) Able and willing to sign the written form. (8) Willing to return for all scheduled follow-up visits and examinations. Exclusion Criteria: (1) Presence of thrombus in the left atrium or left atrial appendage identified on preoperative imaging (echocardiogram, pulmonary vein CT, etc). (2) Major bleeding event (per ISTH definition) within 14 days prior to randomization. Participants must be excluded if clinical sequelae persist or if interventions for the bleeding source are planned/pending, regardless of the time elapsed since the event. (3) Requirement for long-term oral anticoagulation (OAC) for reasons other than stroke risk reduction in AF (e.g., underlying hypercoagulable state) that would prevent OAC discontinuation post-device implantation. (4) Any cardiac or major non-cardiac intervention/surgery (excluding AF ablation and cardioversion) performed within 30 days prior to, or scheduled within 60 days after randomization. This includes but is not limited to Percutaneous Coronary Intervention (PCI) or other cardiac ablations. (5) \< 2 years, , infectious endocarditis, uncontrolled infection, or physiological evidence of cardiac tamponade. (6) Clinical Frailty Scale (CFS) score of 1-3 (not frail) or 7-9 (severely frail/terminally ill). (7) Deemed unsuitable for long-term anticoagulation and/or antiplatelet therapy by the investigator due to bleeding risk, allergies, or other reasons. (8) Current participation in another clinical trial that interferes with this study, excluding mandatory government or purely observational registries. (9) Stroke or (TIA) within 60 days prior to randomization. (10) Documented myocardial infarction (NSTEMI or STEMI) within 90 days prior to randomization, regardless of intervention. (11) History of atrial septal defect (ASD) repair or presence of an ASD/Patent Foramen Ovale (PFO) occluder. (12) Presence of a mechanical prosthetic valve in any position. (13) Participants of who are pregnant or planning pregnancy during the study period. (14) Medical or anatomical to percutaneous catheter-based interventions. (15) Documented Class IV heart failure. (16) History of surgical left atrial appendage (LAA) closure.

Transthoracic Echocardiography (TTE) Specific Exclusions: (1) Low : Left ventricular ejection fraction (LVEF) \< 30%. (2) Presence of pericardial effusion with a circumferential echo-free space > 5mm. (3) Presence of high-risk PFO associated with an atrial septal aneurysm (ASA) with an excursion or length > 15mm. (4) Presence of high-risk PFO with a large shunt (defined as appearance of microbubbles within 3 cardiac cycles and/or a substantial count of microbubbles). (5) Presence of moderate or severe mitral stenosis (mitral valve area \< 1.5 cm2).

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    catheter ablation combined with LAAO

    Participants will receive a combined intervention consisting of catheter ablation for rhythm control and percutaneous left atrial appendage occlusion (LAAO) for stroke prevention. These procedures may be performed either during the same operative session (One-Stop) or as separate. This strategy is used as an alternative to long-term oral anticoagulation in elderly patients with a high risk of bleeding.

    Device: catheter ablation combined with LAAO (Left Atrial Appendage Occlusion)

  • Active comparator
    Atrial Fibrillation Radiofrequency Ablation Only

    Participants will receive standard-of-care treatment consisting of catheter ablation followed by long-term oral anticoagulation (OAC) for stroke prevention. This arm follows current clinical guidelines to evaluate baseline efficacy and safety outcomes compared to the device-based strategy.

    Drug: Atrial Fibrillation Radiofrequency Ablation Only

Interventions

  • Devicecatheter ablation combined with LAAO (Left Atrial Appendage Occlusion)

    1. Ablation: CPVI will be performed using the EnSite X system and HD Grid catheter. Additional linear ablation (e.g., mitral isthmus or roof lines) may be added based on the patient's atrial substrate if sinus rhythm is not restored. LAAO: An LAA closure device (Watchman FLX, LAmbre, or LACbes) will be implanted under TEE or ICE guidance. 2. Antithrombotic Regimen: Days 0-90: Participants receive OAC (NOAC or Warfarin). Day 90 to 12 Months: If imaging confirms no DRT and no residual leak ≥ 5 mm, therapy will be de-escalated (e.g., to aspirin monotherapy) at the investigator's discretion.

  • DrugAtrial Fibrillation Radiofrequency Ablation Only

    Atrial Fibrillation Radiofrequency Ablation: Procedures will be performed using the EnSite X 3D mapping system with an HD Grid high-density mapping catheter for atrial modeling, followed by pulmonary vein isolation using any approved ablation catheter. Linear ablation may be added if necessary. Guideline-directed oral anticoagulation (e.g., NOACs or warfarin) will be continued post-procedure.

06

What researchers measure

Primary outcomes

  1. Incidence of Net Adverse Clinical Events (NACE) at 12 Months

    NACE is defined as a composite endpoint consisting of stroke, systemic embolism, and major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. The analysis will measure the time from randomization to the first occurrence of any event within this composite endpoint.

    Time frame: 12 months post-randomization

Secondary outcomes

  1. Incidence of All-Cause Mortality

    The percentage of participants who died from any cause during the follow-up period. All-cause mortality includes both cardiovascular and non-cardiovascular deaths.

    Time frame: 12 months and 24 months post-randomization

  2. Incidence of Cardiovascular Mortality

    Death due to cardiovascular causes, including myocardial infarction, sudden cardiac death, heart failure, stroke, or other vascular causes. Any death for which a non-cardiovascular cause cannot be identified will also be classified as cardiovascular death.

    Time frame: 12 months and 24 months post-randomization

  3. Incidence of Net Clinical Benefit (NCB) at 24 Months

    NCB is defined as a composite endpoint consisting of stroke, systemic embolism, major bleeding (according to ISTH criteria), and all-cause mortality. The analysis will measure the time from randomization to the first occurrence of any event within this composite endpoint at 24 months.

    Time frame: 24 months post-randomization

  4. Incidence of Unplanned Readmission

    The incidence of unplanned rehospitalization, including cardiovascular-related hospitalizations (e.g., heart failure, arrhythmia) and bleeding-related hospitalizations.

    Time frame: 12 months and 24 months post-randomization

  5. Cumulative Incidence of Major Bleeding

    The cumulative incidence of major bleeding events related to antithrombotic therapy, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. This includes fatal bleeding, symptomatic bleeding in a critical area or organ, and bleeding causing a fall in hemoglobin level of 20 g/L or more.

    Time frame: 24 months post-randomization

  6. Cumulative Incidence of Thromboembolic Events

    The cumulative incidence of thromboembolic events, including ischemic stroke, systemic embolism, and device-related thrombosis (DRT) as confirmed by imaging.

    Time frame: 24 months post-randomization

  7. Incidence of Non-major Bleeding

    The percentage of participants experiencing non-major bleeding events, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria, which do not meet the definition of major bleeding but require medical intervention or clinical attention.

    Time frame: 24 months post-randomization

  8. Procedural Success Rate

    The percentage of participants who successfully undergo both atrial fibrillation ablation and left atrial appendage closure (LAAC) device implantation. Success is defined as stable device position with no major complications and no residual peridevice leak (or leak \< 5mm) confirmed by imaging.

    Time frame: During the procedure and for the duration of the index hospitalization (up to 7 days post-procedure).

  9. Total Procedure and Fluoroscopy Duration

    The total time from initial vascular access (puncture) to the removal of all catheters from the body, as well as the total duration of X-ray fluoroscopy exposure during the intervention.

    Time frame: During procedure

  10. Length of Index Hospital Stay

    The total number of days the participant remains hospitalized from the date of admission for the index procedure until the date of discharge.

    Time frame: From the day of admission for the index procedure through the day of discharge, assessed up to 24 months .

  11. Change in Clinical Frailty Scale (CFS) Score

    Assessment of global frailty using the Clinical Frailty Scale (CFS). This judgment-based tool uses descriptions and icons to categorize frailty. The score ranges from 1 (Very Fit) to 9 (Terminally Ill). Higher scores indicate a worse clinical outcome (greater frailty).

    Time frame: Baseline, 6, 12, 18, and 24 months post-randomization.

  12. Change in Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Questionnaire Score

    The change in the AFEQT total score from baseline to 12 months and 24 months. The AFEQT is a 20-item validated instrument used to assess health-related quality of life in patients with atrial fibrillation. The score ranges from 0 (worst) to 100 (best).

    Time frame: Baseline, 6, 12, 18, and 24 months post-randomization.

  13. Change in Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) Scores

    Assessment of functional independence using the Barthel Index for ADL (Basic Activities) and the Lawton Scale for IADL (Instrumental Activities). The Barthel Index ranges from 0 to 100, and the Lawton IADL typically ranges from 0 to 8. For both scales, higher scores indicate a better clinical outcome (greater independence).

    Time frame: Baseline, 6, 12, 18, and 24 months post-randomization.

  14. Change in Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) Score

    Assessment of cognitive impairment using the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). The MMSE total score ranges from 0 to 30, and the MoCA total score ranges from 0 to 30. For both instruments, higher scores indicate a better clinical outcome (better cognitive function).

    Time frame: Baseline, 6, 12, 18, and 24 months post-randomization.

  15. Modified Rankin Scale (mRS) Score Following Stroke Event

    Assessment of disability or dependence in participants who experience a stroke during the study. The scale ranges from 0 (no symptoms) to 6 (dead). Higher scores indicate greater disability.

    Time frame: At stroke occurrence (up to 2 years)

  16. National Institutes of Health Stroke Scale (NIHSS) Score Following Stroke Event

    A tool to measure stroke-related neurological impairment in participants who experience a stroke event. Total score ranges from 0 to 42, with higher scores indicating more severe impairment.

    Time frame: At stroke occurrence (up to 2 years)

  17. Days Alive and Out of Hospital (DAOH) within 12 Months

    DAOH represents a composite measure of mortality and morbidity. It is calculated as the total number of days a participant is alive and not hospitalized during the first 12 months (365 days) after randomization. Any day spent in a hospital or a skilled nursing facility, or any day after death, is excluded from DAOH.

    Time frame: From randomization up to 12 months

  18. Incidence of Major Adverse Cardiovascular Events (MACE) by Atrial Fibrillation Subtypes

    Comparison of MACE incidence between participants with paroxysmal atrial fibrillation (pAF) and persistent atrial fibrillation (perAF). MACE is defined as a composite of cardiovascular death, stroke, and systemic embolism.

    Time frame: From randomization up to 24 months

  19. Incidence of Acute Major Adverse Events (MAE)

    The incidence of serious intraoperative complications and MAE within 7 days post-procedure. MAE includes, but is not limited to, symptomatic pericardial effusion/tamponade, stroke, systemic embolism, major bleeding (per ISTH criteria), or procedure-related death.

    Time frame: From the index procedure up to 7 days

  20. Incidence of Atrial Arrhythmia Recurrence

    Recurrence is defined as any documented episode of atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia (AT) lasting more than 30 seconds. These episodes must be confirmed by electrocardiogram (ECG) or Holter monitoring following a 3-month blanking period post-ablation. The 3-month blanking period allows for post-procedural healing and stabilization, and arrhythmias occurring during this time are not counted as recurrences.

    Time frame: 12 months and 24 months post-randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in the article, after de-identification, will be shared with researchers whose proposed use of the data has been approved.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 6 months and ending 36 months following article publication.

Access criteria: Data will be available to researchers providing a methodologically sound proposal and with signed data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 13 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2026
First posted
Mar 2, 2026
StartActual
Mar 24, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441382
Collaborators
Abbott (China)
Responsible party
Yumei Xue (Director, Guangdong Institute of Geriatrics; Chief Physician, Department of Cardiology, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Mar 2, 2026
Start date
Mar 24, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Jun 8, 2026

Study contacts

Yumei Xue, M.D.
Contact
xymgdci@163.com
086 13570082363
Junrong Jiang, M.D.
Contact
jrkgdci@163.com
086 15817182813

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion